Yahoo Web Search

Search results

1. profiles.ucl.ac.uk › 65368Gert Attard Profile - University College London

   profiles.ucl.ac.uk › 65368

   Jan 1, 2018 · Prof Gerhardt Attard MD PhD FRCPProf Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. He holds an advanced Cancer Research UK Clinician Scientist award and is Team Leader of the Treatment Resistance Group at the UCL Cancer Institute. He graduated with a degree in Medicine ...

   • ABOUT

     Prof Gerhardt Attard MD PhD FRCPProf Attard is a John Black...

   • PUBLICATIONS

     Co-authors Attard G, Murphy L, Clarke NW...97 more. PDF...

   • RESEARCH

     Gert Attard Profile page. Professor of Medical...

   • TEACHING

     Gert Attard Profile page. Orcid identifier...

2. www.canceractive.com › article › abiraterone-plusAbiraterone plus Prednisolone - new standard of care for ...

   www.canceractive.com › article › abiraterone-plus

   • Cached

   Sep 26, 2021 · This subsection of the study was led by Gerhardt Attard, MD, PhD, John Black Charitable Foundation endowed chair in urological cancer research at University College London. He now believes the findings should be used as a new ‘Standard of Care’.

3. www.attardlab.com › meet-the-teamMeet the Team - Attard Lab

   www.attardlab.com › meet-the-team

   • Cached

   Prof Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. He holds an advanced Cancer Research UK Clinician Scientist award and is Team Leader of the Treatment Resistance Group at the UCL Cancer Institute.

4. ascopost.com › news › september-2021PEACE-1 and STAMPEDE Trials: Abiraterone Acetate Plus ...

   ascopost.com › news › september-2021

   • Cached

   Sep 23, 2021 · Study author Gerhardt Attard, MD, PhD, John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London, said, “Based on these results, all men with high-risk nonmetastatic prostate cancer should be considered for 2 years of abiraterone.

5. www.ucl.ac.uk › cancer › researchResearch Profile Prof Gerhardt Attard | UCL Cancer Institute ...

   www.ucl.ac.uk › cancer › research

   • Cached

   Prof Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. He holds an advanced Cancer Research UK Clinician Scientist award and is Team Leader of the Treatment Resistance Group at the UCL Cancer Institute.

6. www.thelancet.com › journals › lancetAbiraterone acetate and prednisolone with or without ...

   www.thelancet.com › journals › lancet

   Jan 29, 2022 · Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.

7. People also ask

   Who is Prof Attard?

   • Prof Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. He holds an advanced Cancer Research UK Clinician Scientist award and is Team Leader of the Treatment Resistance Group at the UCL Cancer Institute.

   Meet the Team | Attard Lab

   www.attardlab.com/meet-the-team

   See all results for this question

   What Awards does Prof Attard have?

   • Prof Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investigator Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010.

   Research Profile Prof Gerhardt Attard | UCL Cancer

   www.ucl.ac.uk/cancer/research/department-oncology/treatment-resistance-group/research-profile-prof-gerhardt-attard

   See all results for this question

   Should abiraterone and docetaxel be added to ADT?

   • In 2015, docetaxel, a chemotherapy agent, was shown to improve survival when added to ADT and in 2017, abiraterone, a next-generation hormonal agent, was also shown to improve survival when added to ADT. Until now, though, it was unknown whether one or both agents should be added to ADT to achieve the best outcomes.

   PEACE-1 and STAMPEDE Trials Abiraterone Acetate Plus ... - ASCO Post

   ascopost.com/news/september-2021/peace-1-and-stampede-trials-abiraterone-acetate-plus-prednisolone-in-prostate-cancer/

   See all results for this question

8. www.urotoday.com › conference-highlights › esmo-2021ESMO 2021: Abiraterone Acetate Plus Prednisolone With or ...

   www.urotoday.com › conference-highlights › esmo-2021

   • Cached

   Dr. Attard ended by summarizing that two years of AAP-based therapy significantly improved MFS and OS in men with high-risk M0 prostate cancer starting ADT. Adding ENZ to AAP increased toxicity with no discernible impact on efficacy.